Glenmark inks pact with SaNOtize to produce, market anti-COVID-19 nasal spray in India, other countries
The Hindu
Available in the form of a nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs
Canadian biotech firm SaNOtize Research & Development Corp. has entered into an exclusive long term agreement with Glenmark Pharmaceuticals Ltd for the manufacturing, marketing and distribution of its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India. Glenmark will also be handling other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam. “In March 2021, SaNOtize’s clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms,” Glenmark said in a statement.More Related News
According to BACL, the biophilic-inspired business park will offer smart workspaces within a vibrant public realm. The project’s most exceptional and breathtaking attribute lies in the Urban Forest, a lush oasis in the centre of the development. This green space will serve as a focal point, seamlessly blending indoor and outdoor spaces throughout the area. The upcoming metro station in Airport City will provide seamless connectivity to the business park from the northern side, ensuring convenient accessibility.